SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
________________
Date of Report (Date of earliest event reported):
October 30, 2000
Alpharma Inc.
(Exact name of registrant as specified in its charter)
Delaware 1-8593 22-2095212
(State or other (Commission (IRS
Employer
jurisdiction of File Number) Identification
incorporation) No.)
One Executive Drive, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(201) 947-7774
Not Applicable
________________________________________________
(Former name or former address, if changed since
last report)
Item 5. Other Events
As a part of a press release issued on October 30, 2000, which
among other matters announced a restatement of certain previously
issued financial statements, the Company attached as reported and
as restated income statements and condensed balance sheets for
each of the first three fiscal quarters of 1999, the year ended
December 31, 1999 and the first two fiscal quarters of 2000. The
Company intends to amend all affected reports previously filed
under the Securities and Exchange Act of 1934, as soon as
practical.
Copies of this attachment to the press release have been filed
with this current report on Form 8-K as Exhibit 99.1 and are
incorporated herein by reference.
Item 9. Regulation FD Disclosures
On October 30, 2000, the Company issued a press release
announcing third quarter 2000 earnings and the planned
restatement of its financial statements for 1999 and the first
and second quarters of 2000.
Copies of the press release (without the attachments described
under Item 5 and filed as Exhibit 99.1) have been filed with this
current report on Form 8-K as Exhibit 99.2 and are incorporated
herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information
and Exhibits
(c) Exhibits
Exhibits Exhibit Description
99.1 Certain financial information relating to a restatement of
the Company's financial statements.
99.2 Press Release dated October 30, 2000 (without
the material attached as Exhibit 99.1)
Signatures
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Alpharma Inc.
By: /s/Jeffrey E. Smith
Jeffrey E. Smith
Executive Vice President and
Chief Financial Officer
Date: October 31, 2000
